GPER-1 agonist G1 induces vasorelaxation through activation of epidermal growth factor receptor-dependent signalling pathway

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 10, 2013, Pages 1488-1499

  Jang, Eun Jin ^a   Seok, Young Mi ^a   Arterburn, Jeffrey B ^b   Olatunji, Lawrence A ^c,d   Kim, In Kyeom ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b NEW MEXICO STATE UNIVERSITY   (United States)

^c Department of Physiology Cardiovascular and Membrane Physiology   (United States)

^d UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

endothelium dependent vasorelaxation; epidermal growth factor receptor; G protein coupled oestrogen receptor 1; G1; Src and PI3K Akt pathway

Indexed keywords

1 [4 (6 BROMO 1,3 BENZODIOXOL 5 YL) 3A,4,5,9B TETRAHYDRO 3H CYCLOPENTA[C]QUINOLIN 8 YL]ETHANONE; 1,4 DIAMINO 2,3 DICYANO 1,4 BIS(O AMINOPHENYLMERCAPTO)BUTADIENE MONOETHANOLATE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (6 BROMO 1,3 BENZODIOXOL 5 YL) 3A,4,5,9B TETRAHYDRO 3H CYCLOPENTA[C]QUINOLINE; 4 AMINO 3 (4 CHLOROPHENYL) 1 (TERT BUTYL) 1H PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4,5 DIANILINOPHTHALIMIDE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; EPIDERMAL GROWTH FACTOR RECEPTOR; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; METHYLPIPERIDINO PYRAZOLE; N(G) NITROARGININE METHYL ESTER; PHTHALIMIDE DERIVATIVE; POTASSIUM CHLORIDE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; MALE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; VASODILATATION;

ENDOTHELIUM-DEPENDENT VASORELAXATION; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN-COUPLED OESTROGEN RECEPTOR-1; G1; SRC AND PI3K/AKT PATHWAY;

ANIMALS; AORTA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; MALE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 84883741018     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12113     Document Type: Article

References (40)

1. Oh DY, et al. Cellular and molecular biology of orphan G protein-coupled receptors. Int Rev Cytol 2006; 252: 163-218.
2. Haas E, et al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 2009; 104: 288-291.
3. Haas E, et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007; 49: 1358-1363.
4. Isensee J, et al. Expression pattern of G protein-coupled receptor 30 in LacZ reporter mice. Endocrinology 2009; 150: 1722-1730.
5. Takada Y, et al. Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem Biophys Res Commun 1997; 240: 737-741.
6. Bologa CG, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006; 2: 207-212.
7. Dennis MK, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009; 5: 421-427.
8. Lindsey SH, et al. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 2009; 150: 3753-3758.
9. Broughton BR, et al. Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. Am J Physiol Heart Circ Physiol 2010; 298: H1055-H1061.
10. Lindsey SH, et al. Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. J Cardiovasc Pharmacol 2011; 57: 598-603.
11. Hisayama T, et al. Tyrosine kinase may participate in Ca2+ entry for endothelial nitric oxide production. Jpn J Pharmacol 1995; 67: 181-183.
12. Filardo EJ, Thomas P,. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 2005; 16: 362-367.
13. Filardo EJ,. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 2002; 80: 231-238.
14. Lin AH, et al. Genistein enhances relaxation of the spontaneously hypertensive rat aorta by transactivation of epidermal growth factor receptor following binding to membrane estrogen receptors-α and activation of a G protein-coupled, endothelial nitric oxide synthase-dependent pathway. Pharmacol Res 2011; 63: 181-189.
15. Rowlands DJ, et al. Equol-stimulated mitochondrial reactive oxygen species activate endothelial nitric oxide synthase and redox signaling in endothelial cells: roles for F-actin and GPR30. Hypertension 2011; 57: 833-840.
16. Prossnitz ER, et al. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci 2008; 29: 116-123.
17. Sharma G, Prossnitz ER,. Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. Endocrinology 2011; 152: 3030-3039.
18. Burai R, et al. Highly efficient synthesis and characterization of the GPR30-selective agonist G-1 and related tetrahydroquinoline analogs. Org Biomol Chem 2010; 8: 2252-2259.
19. Seok YM, et al. Isoflavone attenuates vascular contraction through inhibition of the RhoA/Rho-kinase signaling pathway. J Pharmacol Exp Ther 2008; 326: 991-998.
20. Daub H, et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996; 379: 557-560.
21. Prenzel N, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of pro HB-EGF. Nature 1999; 402: 884-888.
22. Chen K, et al. c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent epidermal growth factor receptor transactivation. J Biol Chem 2001; 276: 16045-16050.
23. Hsieh HL, et al. c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells. J Neuroinflammation 2012; 9: 152.
24. Ge C, et al. G protein-coupled receptor 30 mediates estrogen-induced proliferation of primordial germ cells via EGFR/Akt/β-catenin signaling pathway. Endocrinology 2012; 153: 3504-3516.
25. Haynes MP, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000; 87: 677-682.
26. Revankar CM, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630.
27. Thomas P, et al. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146: 624-632.
28. Thompson LP, et al. Chronic 17beta-estradiol replacement increases nitric oxide-mediated vasodilation of guinea pig coronary microcirculation. Circulation 2000; 102: 445-451.
29. Traupe T, et al. Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 2007; 49: 1364-1370.
30. Brouchet L, et al. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 2001; 103: 423-428.
31. Pare G, et al. Estrogen receptor-α mediates the protective effects of estrogen against vascular injury. Circ Res 2002; 90: 1087-1092.
32. Vegeto E, et al. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci U S A 2003; 100: 9614-9619.
33. Meyer MR, et al. Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780. Pharmacology 2010; 86: 58-64.
34. Seok YM, et al. 17β-Estradiol induces vasorelaxation in a G-protein-coupled receptor 30-independent manner. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 945-948.
35. Shah BH, Catt KJ,. Calcium-independent activation of extracellularly regulated kinases 1 and 2 by angiotensin II in hepatic C9 cells: roles of protein kinase Cdelta, Src/proline-rich tyrosine kinase 2, and epidermal growth receptor trans-activation. Mol Pharmacol 2002; 61: 343-351.
36. Thomas WG, et al. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 2002; 90: 135-142.
37. Asakura M, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8: 35-40.
38. Li ZL, et al. Improvement of vascular function by acute and chronic treatment with the GPR30 agonist G1 in experimental diabetes mellitus. PLoS ONE 2012; 7: e38787.
39. Atochin DN, Huang PL,. Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pflugers Arch 2010; 460: 965-974.
40. Olde B, Leeb-Lundberg LM,. GPR30/GPER1: searching for a role in estrogen physiology. Trends Endocrinol Metab 2009; 20: 409-416